格隆汇1月12日丨三叶草生物-B(02197.HK)宣布，基于公司自研独有的 Trimer-Tag(蛋白质三聚体化)疫苗 研发平台开发的 Pre-F 三聚体亚单位重组蛋白呼吸道联合疫苗候选产品 SCB-1022(RSV+hMPV) 与 SCB- 1033 (RSV+hMPV+PIV3) 在澳大利亚已完成首批受试者入组，正式启动 2 期临床试验。 正在澳大利亚进行的三叶草生物呼吸道联合疫苗候选产品的 2 期临床试验，是一项随机、观察者设盲、 多中心研究的临床试验，计划招募至多 420 名(60-85 岁)的老年受试者；他们将随机接种 SCB- 1022(RSV+hMPV)、SCB-1033(RSV+hMPV+PIV3)或安慰剂。该研究将评估疫苗的安全性、反应原性及 免疫原性。 ...

Core Viewpoint - The stock of Clover Biopharmaceuticals-B (02197) has surged over 21%, reaching HKD 2.75 with a trading volume of HKD 42.22 million, following the announcement of the initiation of Phase I clinical trials for its respiratory combination vaccine candidates SCB-1022 and SCB-1033 [1] Group 1 - Clover Biopharmaceuticals has completed the enrollment of the first batch of trial participants for its RSV+hMPV vaccine candidate SCB-1022 and the RSV+hMPV+PIV3 candidate SCB-1033, marking the official start of Phase I clinical trials [1] - The CEO of Clover Biopharmaceuticals, Liang Guo, highlighted that while currently approved recombinant protein RSV vaccines are safe and effective, there remains a significant unmet clinical need globally [1] - The unmet clinical needs include the inability to prevent and alleviate respiratory diseases caused by human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3), which are structurally similar to RSV [1]